XML 61 R49.htm IDEA: XBRL DOCUMENT v3.21.1
License Agreements - Merus (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 23, 2017
USD ($)
$ / shares
Jan. 31, 2021
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Jan. 31, 2017
USD ($)
item
Dec. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2020
USD ($)
License agreements                  
Long term investments           $ 202,174     $ 222,301 [1]
Research and development expense           306,896 $ 1,085,287    
Unrealized gain (loss) on long term investments           (27,709) (48,132)    
Total revenues           604,718 568,507    
Net income (loss)           53,535 (720,642)    
Current assets           2,449,969     2,359,894 [1]
Current liabilities           623,881     631,195 [1]
Merus                  
License agreements                  
Number of independent programs | item       11          
Number of preclinical discovery programs | item       2          
Number of programs under the resulting products are co-funded for development | item       1          
Associated future global development costs , if elected to co-develop (as a percent)       35.00%          
Upfront payment under license agreement     $ 120,000            
Research and development expense           2,300 2,300    
Merus | Accrued and other liabilities                  
License agreements                  
Accrued and other liabilities           1,600     1,600
Merus | U.S.                  
License agreements                  
Profit sharing (as a percent)       50.00%          
Percentage of profit (losses)       50.00%          
Merus | Minimum                  
License agreements                  
Royalty payments on future global net sales (as a percent)       6.00%          
Merus | Minimum | U.S.                  
License agreements                  
Royalty payments on future global net sales (as a percent)       6.00%          
Merus | Minimum | Non-U.S.                  
License agreements                  
Royalty payments on future global net sales (as a percent)       6.00%          
Merus | Maximum                  
License agreements                  
Number of additional preclinical discovery programs | item       10          
Royalty payments on future global net sales (as a percent)       10.00%          
Percentage of reverse royalty       4.00%          
Merus | Maximum | U.S.                  
License agreements                  
Royalty payments on future global net sales (as a percent)       10.00%          
Percentage of additional royalties       4.00%          
Merus | Maximum | Non-U.S.                  
License agreements                  
Royalty payments on future global net sales (as a percent)       10.00%          
Merus | Maximum | Development and Regulatory Milestones                  
License agreements                  
Additional milestone payments under the license agreement       $ 100,000          
Merus | Maximum | Sales and Commercial Milestones                  
License agreements                  
Additional milestone payments under the license agreement       $ 250,000          
Merus | IPO                  
License agreements                  
Common shares purchased (in shares) | shares   350,000              
Number of shares in underwritten public offering (in shares) | shares   4,848,485              
Per share price | $ / shares   $ 24.75              
Value of shares acquired   $ 8,700              
Merus | Stock purchase agreement                  
License agreements                  
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares         3,200,000        
Purchase price of common stock         $ 80,000        
Per share price | $ / shares $ 24.50       $ 25.00        
Discount for lack of marketability $ 5,600                
Fair value of shares on the issuance date 72,800                
Total consideration paid $ 80,000                
Long term investments               $ 72,800  
Research and development expense               $ 7,200  
Fair market value of our long term investments           $ 74,200     $ 56,100
Ownership percentage (as a percent)           9.00%      
Unrealized gain (loss) on long term investments           $ (9,400) $ (6,300)    
[1] The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date.